Dr. Djaballah has several years of industrial experience in early drug discovery gained over the years in pharma and biotech companies. He has extensive experiences in the areas of fluorescence technology, assay development, automation/robotics, HTS, compound & screening data management, software development & novel technologies. Dr Djaballah has been involved in developing and screening several targets in various therapeutic areas, including antibacterials, antivirals, antifungals, diabetes, CNS, cardiovascular, oncology & inflammation. He is currently the director of the high throughput drug screening core facility at Memorial Sloan Kettering Cancer Centre in New York. He obtained his BSc (Hons.) in biochemistry and biotechnology from the University of Birmingham, and his PhD in biochemistry from the University of Leicester, both in England.
An Arrayed shRNA Genomewide RNAi Screen against Dengue Reveals Common Host-Virus Gene Signatures: Implications in Anti-Viral Drug Discovery and Re-purposing”
I will describe the execution of a virus-host interaction RNAi screen for Dengue against an arrayed lentiviral enabled shRNA library with two readouts assessing viral infection and host viability. The resulting targets offer a new opportunity for antiviral drug discovery through repurposing existing molecules.
Add to Calendar ▼2012-10-30 00:00:002012-10-31 00:00:00Europe/LondonIndian Lab AutomationIndian Lab Automation in Mumbai, IndiaMumbai, IndiaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com
